Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...
Zacks Investment Research on MSN
Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
Insulet Corporation PODD reported third-quarter 2025 adjusted earnings per share (EPS) of $1.24, up 37.8% from the year-ago ...
NEW YORK, NY - November 6, 2025 ( NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...
The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Dexcom, Inc. securities during the class period because the Company ...
Now, it’s worth noting Stock Advisor's total average return is 1,064% — a market-crushing outperformance compared to 194% for ...
Kessler Topaz Meltzer & Check, LLP encourages DexCom investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO ...
Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...
DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...
Kirby McInerney LLP reminds investors who purchased DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) securities to contact Thomas W. Elrod of Kirby ...
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. securities between July 26, 2024 and September 17, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback